Secondary hyperlipoproteinemia.

Pathogenesis of hyperlipoproteinemia.

In the past 25 years, great advances have been made in our understanding of lipoprotein metabolism and of the causation of hyperlipidemia. These advances have been due in part to the study of patients with unusual defects in lipoprotein metabolism. Follow-up investigations into the specific metabolic defects in these patients have revealed qualitative abnormalities in the structure and function...

Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)

General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-base...

Diabetes mellitus in familial hyperlipoproteinemia.

The relationship between a certain form of type 2 diabetes mellitus and familial endogenous hyperlipoproteinemia still remains confused. Therefore, we examined glucose tolerance and insulin secretion in 133 members (6-80 years old) of 15 families with a history of endogenous hyperlipoproteinemia. A segregation study was carried out to compare the prevalence of diabetes in hyperlipoproteinemic a...

Hyperlipoproteinemia impairs endothelium-dependent vasodilation.

Atherogenic lipoproteins can cause endothelial dysfunction in the initial stage of atherogenesis. In our study we examined 134 patients with defined hyperlipoproteinemia (non-HDL cholesterol>4.1 mmol/l or triglycerides>2.5 mmol/l or taking any of lipid lowering drugs)--94 men and 40 women. The subgroup of controls of comparable age contained 54 normolipidemic individuals--30 men and 24 women. P...

Erythrocyte Antioxidant Enzymes in Hyperlipoproteinemia